Peps
What is Adipotide?
Adipotide is a peptidomimetic designed to target blood vessels in adipose tissue. Its featured study reported weight-related changes in obese monkeys and also identified kidney effects.
Biological role or research focus
Adipose vascular targeting in primates.
Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.
Role reference: A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. · 2011 ↗
Names you may encounter
FTPP · Fat-targeted proapoptotic peptide
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Experimental fat-vascular-targeting peptidomimetic
- Research focus
- Adipose vascular targeting in primates
- Featured evidence
- Animal study
- Source check
- October 4, 2026
Biology & proposed mechanism
The experimental strategy combines adipose-vascular targeting with a proapoptotic component. It differs from incretin-based appetite signaling.
Research context & identity
This is preclinical obesity research in nonhuman primates. The findings do not establish an effective or safe human weight-loss treatment.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal study · 2011
Adipotide in obese nonhuman primates
What did this publication test, and what did it find?
- Population / model
- Obese Old World monkeys.
- Study design
- Animal intervention assessing weight, adipose tissue, insulin resistance, and safety measures.
- Main finding
- The investigators reported reductions in body weight and adipose tissue, with improved insulin-resistance measures. Renal proximal-tubule changes were also observed.
- Limits & context
- Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 2 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. ↗
Journal of controlled release : official journal of the Controlled Release Society · 2013 Oct 28 · Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys". ↗
Science translational medicine · 2012 Apr 25 · Journal Article, Comment
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
Kidney tubular effects are a material finding in this study and should remain prominent in summaries.
Evidence boundaries
Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
4 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Adipotide (FTPP) Nedir? Yağ Hücrelerini Yok Eden Peptit ↗
Title match · Captions not indexed
Biohackingturkey
Adipotide Nedir? Yağ Yakımı İçin Geliştirilen Peptit Hakkında Bilmeniz Gerekenler ↗
Title match · Captions not indexed
Biohackingturkey
Adipotide Peptidi Nedir? Yağ Hücrelerini Yok Eden Teknoloji ↗
Title match · Captions not indexed
Biohackingturkey
FTPP Adipotide Nedir? Yağ Hücrelerini Hedefleyen Peptit 🚀 ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
Adipotide (2 mg / 5 mg)
PSPeptides · Vendor-labeled research use only
$34.99–$69.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Were kidney effects reported?
- What material, population, and route were actually studied?
- Primate results do not establish human efficacy. The reported reversibility of kidney changes does not make them unimportant or prove clinical safety.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Were kidney effects reported?
Yes. The publication described predictable, reversible proximal-tubule changes in its animal setting; this is not evidence that human kidney risk is absent.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.